166 related articles for article (PubMed ID: 32469607)
21. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
22. Formulation development and characterization of lumefantrine nanosuspension for enhanced antimalarial activity.
Shah R; Soni T; Shah U; Suhagia BN; Patel MN; Patel T; Gabr GA; Gorain B; Kesharwani P
J Biomater Sci Polym Ed; 2021 May; 32(7):833-857. PubMed ID: 33380264
[TBL] [Abstract][Full Text] [Related]
23. Fabrication of an aprepitant nanosuspension using hydroxypropyl chitosan to increase the bioavailability.
Liu J; Li S; Ao W; Li Y; Xiao Y; Bai M
Biochem Biophys Res Commun; 2022 Nov; 631():72-77. PubMed ID: 36179498
[TBL] [Abstract][Full Text] [Related]
24. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
25. Production, Characterization and Evaluation of Kaempferol Nanosuspension for Improving Oral Bioavailability.
Qian YS; Ramamurthy S; Candasamy M; Shadab M; Kumar RH; Meka VS
Curr Pharm Biotechnol; 2016; 17(6):549-55. PubMed ID: 26813303
[TBL] [Abstract][Full Text] [Related]
26. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
27. Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies.
Patel HP; Chaudhari PS; Gandhi PA; Desai BV; Desai DT; Dedhiya PP; Vyas BA; Maulvi FA
Int J Pharm; 2021 May; 600():120474. PubMed ID: 33737093
[TBL] [Abstract][Full Text] [Related]
28. Isoliquiritigenin Nanosuspension Enhances Cytostatic Effects in A549 Lung Cancer Cells.
Qiao F; Zhao Y; Mai Y; Guo J; Dong L; Zhang W; Yang J
Planta Med; 2020 May; 86(8):538-547. PubMed ID: 32294789
[TBL] [Abstract][Full Text] [Related]
29. Physicochemical, Pharmacodynamic and Pharmacokinetic Characterization of Soluplus Stabilized Nanosuspension of Tacrolimus.
Varshosaz J; Minayian M; Yazdekhasti S
Curr Drug Deliv; 2017; 14(4):521-535. PubMed ID: 27697037
[TBL] [Abstract][Full Text] [Related]
30. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
[TBL] [Abstract][Full Text] [Related]
31. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
32. Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor.
Na YG; Pham TMA; Byeon JJ; Kim MK; Han MG; Baek JS; Lee HK; Cho CW
Int J Pharm; 2020 May; 581():119287. PubMed ID: 32243963
[TBL] [Abstract][Full Text] [Related]
33. Improved Oral Bioavailability of Lacidipine Using Nanosuspension Technology: Inferior in vitro Dissolution and Superior in vivo Drug Absorption versus Lacipil®.
Zhao J; Luo L; Fu Q; Guo B; Li Y; Geng Y; Wang J; Zhang T
Curr Drug Deliv; 2016; 13(5):764-73. PubMed ID: 25963306
[TBL] [Abstract][Full Text] [Related]
34. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.
Hanafy A; Spahn-Langguth H; Vergnault G; Grenier P; Tubic Grozdanis M; Lenhardt T; Langguth P
Adv Drug Deliv Rev; 2007 Jul; 59(6):419-26. PubMed ID: 17566595
[TBL] [Abstract][Full Text] [Related]
36. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation.
Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B
Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130
[TBL] [Abstract][Full Text] [Related]
37. Ginkgolides-loaded soybean phospholipid-stabilized nanosuspension with improved storage stability and in vivo bioavailability.
Wang P; Cao X; Chu Y; Wang P
Colloids Surf B Biointerfaces; 2019 Sep; 181():910-917. PubMed ID: 31382340
[TBL] [Abstract][Full Text] [Related]
38. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
39. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
40. Development of daidzein nanosuspensions: Preparation, characterization, in vitro evaluation, and pharmacokinetic analysis.
Wang H; Xiao Y; Wang H; Sang Z; Han X; Ren S; Du R; Shi X; Xie Y
Int J Pharm; 2019 Jul; 566():67-76. PubMed ID: 31125715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
